Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
BOLT

Bolt Biotherapeutics (BOLT) stock: insider trades, news & valuation

Health Care · Heavy selling
Close · Oct 9, 2026 $4.11 +12.6% on the day -30.6% over 12 months 52-week range $3.18 – $7.09

Share price and insider trades

BOLT closeInsider buyInsider sale
2468NovDecJan 2026FebMarAprMayJunJulAugSepOctBought $1,152 on 2025-12-05 · Sarah Nemec, William P. QuinnBought $4,446 on 2026-06-05 · Sarah Nemec, William P. QuinnSold $15,642 on 2026-09-16 · Grant Yonehiro, Sarah Nemec, William P. QuinnSold $47,728 on 2026-09-17 · Grant Yonehiro, Sarah Nemec, William P. QuinnSold $64,991 on 2026-09-18 · Grant Yonehiro, Sarah Nemec, William P. Quinn
Bought, 12 months$0
Sold, 12 months$128K
Insiders buying0
Insiders selling3

Bolt Biotherapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 3 sold $128K of BOLT stock on the open market.

BOLT insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q2 2025: $1K bought (2 trades)$1KQ2 2025Q3 2025Q4 2025: $1K bought (2 trades)$1KQ4 2025Q1 2026Q2 2026: $4K bought (2 trades)$4KQ2 2026Q3 2026: $128K sold (9 trades)Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026—0$128K9
Q2 2026$4K2—0
Q1 2026—0—0
Q4 2025$1K2—0
Q3 2025—0—0
Q2 2025$1K2—0

Valuation, profit and volume

P/E (trailing)n/aSector median 24.7
Market value$7.9MBiotechnology
Profit margin0.0%Revenue growth -99.7%
Volume vs. 50-day1.3×Last 5 sessions
Insiders' paper profit−$206On all tracked purchases -3.0%

Summary

Over the past 12 months, 0 Bolt Biotherapeutics, Inc. insiders reported open-market purchases totaling $0, while 3 insiders reported sales totaling $128K. 0 of 9 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

BOLT stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Sep 21SEC William P. QuinnCEO, CFO Sell 9,13225,384 held (−26%) $3.24 $30K +26.9% —
Sep 21SEC Grant YonehiroCOO Sell 6,85017,269 held (−28%) $3.24 $22K +26.9% —
Sep 21SEC William P. QuinnCEO, CFO Sell 6,54534,516 held (−16%) $3.32 $22K +23.8% —
Sep 21SEC Grant YonehiroCOO Sell 4,90924,119 held (−17%) $3.32 $16K +23.8% —
Sep 21SEC Sarah NemecSenior Vp, Finance And Pao Sell 4,07717,082 held (−19%) $3.24 $13K +26.9% —
Sep 21SEC Sarah NemecSenior Vp, Finance And Pao Sell 2,92221,159 held (−12%) $3.32 $10K +23.8% —
Sep 21SEC William P. QuinnCEO, CFO Sell 1,88941,061 held (−4%) $3.77 $7K +9.0% —
Sep 21SEC Grant YonehiroCOO Sell 1,41729,028 held (−5%) $3.77 $5K +9.0% —
Sep 21SEC Sarah NemecSenior Vp, Finance And Pao Sell 84324,081 held (−3%) $3.77 $3K +9.0% —
Sep 21SEC William P. QuinnCEO, CFO Buy 6372,950 held (+28%) $3.88 $2K +5.9% —
Sep 21SEC Sarah NemecSenior Vp, Finance And Pao Buy 5091,924 held (+36%) $3.88 $2K +5.9% —
Feb 4SEC William P. QuinnCEO, CFO Buy 1252,313 held (+6%) $4.61 $576 -10.8% —
Feb 4SEC Sarah NemecSenior Vp, Finance And Pao Buy 1251,415 held (+10%) $4.61 $576 -10.8% —
Oct 24SEC Sarah NemecSenior Vp, Finance And Pao Buy 125943 held (+15%) $5.49 $686 -25.1% —
Oct 24SEC William P. QuinnCEO, CFO Buy 1252,188 held (+6%) $5.49 $686 -25.1% —

Insiders at Bolt Biotherapeutics, Inc.

InsiderBoughtSoldLast filingScore
William P. QuinnCEO, CFO $4K $58K Sep 21, 2026 —
Grant YonehiroCOO — $44K Sep 21, 2026 —
Sarah NemecSenior Vp, Finance And Pao $3K $26K Sep 21, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

BOLT stock: common questions

Are Bolt Biotherapeutics, Inc. insiders buying BOLT stock?

In the past 12 months, 0 insiders reported open-market purchases of BOLT worth $0. The latest was CEO, CFO William P. Quinn bought $2K of BOLT at $3.88 — largest purchase by this insider in our records; raises the stake by 28%.

Are Bolt Biotherapeutics, Inc. insiders selling BOLT stock?

3 insiders reported sales worth $128K over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is BOLT's 52-week range?

Over the past year BOLT has traded between $3.18 and $7.09. It last closed at $4.11 on Oct 9, 2026.